Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sha Jin

Showing results (131-140 of 148) with videos related to

Pageof 15
Sort By:
American Journal of Cancer Research|April 20, 2026
Erratum: Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activationYu Wang, Sha-Sha Jin, Dan-Ting Li, et al.
Nucleic Acids Research|May 31, 2022
Structural basis of transcription activation by Rob, a pleiotropic AraC/XylS family regulatorJing Shi, Fulin Wang, Fangfang Li, et al.
Frontiers in Immunology|February 18, 2025
The cancer-associated fibroblasts interact with malignant T cells in mycosis fungoides and promote the disease progressionYige Zhao, Yong Li, Panpan Wang, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Lipid composition differentiates ferroptosis sensitivity between <i>in vitro</i> and <i>in vivo</i> systemsVivian S Park, Lauren E Pope, Justin Ingram, et al.
Molecular Cancer Therapeutics|May 5, 2017
Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 InhibitorsLloyd T Lam, Xiaoyu Lin, Emily J Faivre, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2010
N-aryl-benzimidazolones as novel small molecule HSP90 inhibitorsMilan Bruncko, Stephen K Tahir, Xiaohong Song, et al.
Cancer Research|September 5, 2025
Lipid Composition Alters Ferroptosis SensitivityVivian S Park, Lauren E Pope, Justin P Ingram, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2007
Discovery of a novel small molecule binding site of human survivinMichael D Wendt, Chaohong Sun, Aaron Kunzer, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Structure-Based Design of A-1293102, a Potent and Selective BCL-X<sub>L</sub> InhibitorZhi-Fu Tao, Xilu Wang, Jun Chen, et al.
Cancer Research|May 3, 2008
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitorChristin Tse, Alexander R Shoemaker, Jessica Adickes, et al.
Pageof 15

Showing results (131-140 of 148) with videos related to

Sort By:
Pageof 15
American Journal of Cancer Research|April 20, 2026
Erratum: Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activationYu Wang, Sha-Sha Jin, Dan-Ting Li, et al.
Nucleic Acids Research|May 31, 2022
Structural basis of transcription activation by Rob, a pleiotropic AraC/XylS family regulatorJing Shi, Fulin Wang, Fangfang Li, et al.
Frontiers in Immunology|February 18, 2025
The cancer-associated fibroblasts interact with malignant T cells in mycosis fungoides and promote the disease progressionYige Zhao, Yong Li, Panpan Wang, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Lipid composition differentiates ferroptosis sensitivity between <i>in vitro</i> and <i>in vivo</i> systemsVivian S Park, Lauren E Pope, Justin Ingram, et al.
Molecular Cancer Therapeutics|May 5, 2017
Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 InhibitorsLloyd T Lam, Xiaoyu Lin, Emily J Faivre, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2010
N-aryl-benzimidazolones as novel small molecule HSP90 inhibitorsMilan Bruncko, Stephen K Tahir, Xiaohong Song, et al.
Cancer Research|September 5, 2025
Lipid Composition Alters Ferroptosis SensitivityVivian S Park, Lauren E Pope, Justin P Ingram, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2007
Discovery of a novel small molecule binding site of human survivinMichael D Wendt, Chaohong Sun, Aaron Kunzer, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Structure-Based Design of A-1293102, a Potent and Selective BCL-X<sub>L</sub> InhibitorZhi-Fu Tao, Xilu Wang, Jun Chen, et al.
Cancer Research|May 3, 2008
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitorChristin Tse, Alexander R Shoemaker, Jessica Adickes, et al.
Pageof 15